ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,370
+920 (5.95%)
At close: Dec 5, 2025
10.38%
Market Cap 178.46B
Revenue (ttm) 5.91B
Net Income (ttm) -17.78B
Shares Out 10.90M
EPS (ttm) -1,643.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 522,763
Average Volume 192,007
Open 16,030
Previous Close 15,450
Day's Range 15,050 - 16,420
52-Week Range 10,000 - 22,800
Beta n/a
RSI 77.88
Earnings Date n/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.

Financial Statements

News

There is no news available yet.